$DELL

Here are Tuesday's biggest analyst calls: Nvidia, SpaceX, Netflix, Marvell, AMD, Coinbase, Moderna & more

Analysts made several calls on Tuesday. JPMorgan raised Dell's price target to $565, citing expected revenue growth. Wolfe upgraded Moderna to peer perform, noting its focus on therapeutics. UBS upgraded Fluence to neutral, seeing an earnings trough. Morgan Stanley upgraded Dynatrace to overweight, forecasting growth. Goldman initiated Jersey Mike's as neutral, citing full valuation. Wolfe upgraded Netflix to outperform, raising its price target to $95. Bank of America reiterated Nvidia, Micron,

Original reporting
Published Aug 25, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 2:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here are Tuesday's biggest analyst calls: Nvidia, SpaceX, Netflix, Marvell, AMD, Coinbase, Moderna & more — source image
Decision brief

The 30-second read

$DELLBullishLow
01

Why it matters

The collective rating changes may generate modest buying pressure but lack underlying new fundamentals.

02

Market read

The article is a post-earnings analyst reaction roundup with limited actionable insight.

03

What to watch

Absence of new earnings or macro catalysts reduces the durability of these rating changes.

Relevance 5/10Novelty 2/10Timing: today

Background

Analyst houses released a series of upgrades, initiations, and price target adjustments across a range of US-listed companies.

Company-level read

Ticker impact

$DELLBullishMedium confidence
Context

JPMorgan raised price target to $565 ahead of earnings.

Expected impact

Modest upside if earnings beat expectations.

Evidence & confidence

Analyst upgrade signals confidence but no new earnings data.

$MRNABullishMedium confidence
Context

Wolfe upgrades Moderna to peer perform.

Expected impact

Potential modest rally.

Evidence & confidence

Upgrade without new data.

$CURBBullishMedium confidence
Context

Jefferies initiates Curbline Properties as buy.

Expected impact

Small upside potential.

Evidence & confidence

First coverage may draw attention.

$FLNCNeutralLow confidence
Context

UBS upgrades Fluence to neutral from sell.

Expected impact

Limited price movement.

Evidence & confidence

Upgrade reflects outlook, no new fundamentals.

$SHWBullishMedium confidence
Context

DA Davidson initiates Sherwin-Williams as buy with $400 PT.

Expected impact

Potential upside if earnings sustain.

Evidence & confidence

Analyst confidence but no fresh data.

$DTBullishMedium confidence
Context

Morgan Stanley upgrades Dynatrace to overweight.

Expected impact

Modest upside.

Evidence & confidence

Analyst view without new earnings.

$JMKENeutralLow confidence
Context

Goldman Sachs initiates Jersey Mike's as neutral.

Expected impact

Sideways to slight downside.

Evidence & confidence

Initiation without catalyst.

$FIVEBearishLow confidence
Context

Loop downgrades Five Below to hold from buy.

Expected impact

Potential modest decline.

Evidence & confidence

Downgrade alone.

Market effects

Broad analyst upgrades may lift sector sentiment in tech and consumer discretionary.

US market sentiment modestly positive due to multiple buy/overweight calls.

Limited global impact; primarily US equity focus.

Counterpoint

Many upgrades may be premature without fresh earnings data; price targets could be overstated.

Key entities

  • JPMorgan

    Raised Dell target

  • Wolfe

    Upgraded Moderna, Bread Financial, Netflix

Related articles

$MRNAHighAI 8/10

Moderna stock’s 17% slump was a ‘sell the news’ event, analyst says

Moderna (MRNA) shares fell 17.6% on Oct. 22 after Phase 3 trial results for its cancer vaccine were leaked. The drop occurred despite positive results for the vaccine, developed with Merck (MRK). Analysts attributed the decline to a 'sell the news' event, with Bernstein maintaining a $45 price target and Wells Fargo suggesting concerns may be overdone. Merck shares also dropped 1.76%.

$MRNAMedAI 8/10

A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%

Moderna and Merck's personalized cancer vaccine, intismeran, reduced melanoma recurrence by 42% in a Phase 3 trial. The vaccine, combined with Keytruda, trains the immune system to target tumor proteins. The study involved 1,130 patients, with results replicating earlier Phase 2 data. The effect was noted after six months, suggesting the immune system needs time to activate.

$INTCMed

Why Intel Stock Fell Today

Intel (INTC) stock dropped 8.1% on Oct. 22 amid rising oil prices and AI spending concerns. Brent crude reached $112/barrel. The S&P 500 and Nasdaq fell 1.2% and 2.6%, respectively. High oil prices and rising Treasury yields may impact AI industry financing. Meta's Q3 earnings showed negative free cash flow, raising funding concerns.